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Tau and atrophy: domain-specific
relationships with cognition
Leonardino A. Digma1, John R. Madsen1, Emilie T. Reas1, Anders M. Dale1,2,3,4, James B. Brewer1,2,
Sarah J. Banks1,4* and for the Alzheimer’s Disease Neuroimaging Initiative
Abstract
Background: Late-onset Alzheimer’s disease (AD) is characterized by primary memory impairment, which then
progresses towards severe deficits across cognitive domains. Here, we report how performance in cognitive
domains relates to patterns of tau deposition and cortical thickness.
Methods: We analyzed data from 131 amyloid-β positive participants (55 cognitively normal, 46 mild cognitive
impairment, 30 AD) of the Alzheimer’s Disease Neuroimaging Initiative who underwent magnetic resonance
imaging (MRI), flortaucipir (FTP) positron emission tomography, and neuropsychological testing. Surface-based
vertex-wise and region-of-interest analyses were conducted between FTP and cognitive test scores, and between
cortical thickness and cognitive test scores.
Results: FTP and thickness were differentially related to cognitive performance in several domains. FTP-cognition
associations were more widespread than thickness-cognition associations. Further, FTP-cognition patterns reflected
cortical systems that underlie different aspects of cognition.
Conclusions: Our findings indicate that AD-related decline in domain-specific cognitive performance reflects
underlying progression of tau and atrophy into associated brain circuits. They also suggest that tau-PET may have
better sensitivity to this decline than MRI-derived measures of cortical thickness.
Keywords: Tau, Atrophy, Thickness, Positron emission tomography, Magnetic resonance imaging, Neuropsychology,
Cognition, Surface-based analysis
Background
Alzheimer’s disease (AD) typically presents clinically as an
amnestic disorder with subsequent progression to other
cognitive domains such as visuospatial abilities, language,
and executive function [1]. The domains of cognition rely
on distinct cortical systems, where distributed and special-
ized brain circuitry serves associated cognitive functions
[2]. Degeneration and dysfunction of these large-scale
cortical systems parallel the decline of specific cognitive
domains observed in dementia [3].
Pathological events in AD are considered to cause the
clinical manifestations through sequential and synergistic
build-up of pathological proteins, amyloid-β (Aβ) and tau,
in the brain and neurodegeneration. Although there is
some evidence that elevated levels of Aβ are associated
with future cognitive decline [4], regional Aβ is generally a
poor correlate of cross-sectional cognition [5, 6]. Tau and
neurodegeneration, on the other hand, have been shown
to be closely linked to deficits in cognition [7, 8]. While
the associations with tau have been determined through
studies of post-mortem brain tissue [9], we are now able
to study them in vivo using PET ligands [10, 11].
Autopsy data indicate that the spread of tau pathology
follows a progressive sequence [12] consistent with the
observed clinical course in AD: tau starts in the medial
temporal lobe regions that are responsible for learning and
memory, then into the rest of the cortex to affect the cor-
tical areas that serve other cognitive domains. Initial studies
using tau-binding radiotracers have recapitulated the Braak
staging of tau that has been described in autopsy studies
[13, 14], establishing the promise of these radiotracers for
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assessing, in vivo, how tau pathology relates to domain-spe-
cific cognitive decline.
Assessment of neurodegeneration in vivo has been avail-
able with high-resolution magnetic resonance imaging
(MRI) measures of cortical thickness to estimate structural
atrophy and with fluorodeoxyglucose (FDG)-PET to
evaluate regional hypometabolism. Studies using these
modalities have consistently shown that AD is character-
ized by degeneration in temporal and parietal cortices
[15–18] in a pattern similar to tau pathology. Further-
more, in vivo studies of neurodegeneration, like post-mor-
tem studies of tau, have revealed close associations
between the distribution of neurodegeneration and cogni-
tive deficits found in patients with AD [3, 19–23].
Taken together, studies of tau and neurodegeneration
suggest that the two are closely related and that both con-
tribute to variability in cognitive performance. The relation-
ship between neurodegeneration and cognition across
different domains in vivo has been explored extensively, but
the link between tau and cognition across domains in vivo
remains to be fully characterized. Studies of tau-PET in
early-onset atypical variants of AD, such as primary pro-
gressive aphasia or posterior cortical atrophy, have shown
that tau accumulation in cortical systems that serve specific
cognitive domains is associated with impairment in those
respective domains [24, 25]. Interestingly, the aggregation
of tau within functional cortical systems [26] and the asso-
ciation of tau with cognitive loss in different domains [27]
has recently been demonstrated to similarly occur in late-
onset, amnestic AD. In this study, our interest was to fur-
ther examine how in vivo measures of tau and neurodegen-
eration associate with different domains of cognition in the
common, amnestic AD phenotype.
To this end, we used multi-modal imaging and neuro-
psychological battery data available in the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) to investigate
the relationship between cross-sectional measures of tau,
cortical thickness, and different aspects of cognition. We
hypothesized that tau and cortical thickness would both
correlate with cognition in a domain-specific manner,
with tau demonstrating stronger associations over a
wider area of the domain-relevant cortex. We tested
these hypotheses by performing surface-based vertex-
wise analysis and region-of-interest (ROI) analysis in a
group of Aβ-positive older adults with a diagnosis of
cognitively normal, mild cognitive impairment, or AD.
Methods
Study participants
Our sample consisted of subjects from phase 2 and phase
3 of the ADNI. The ADNI was launched in 2003 as a pub-
lic-private partnership, led by Principal Investigator Mi-
chael W. Weiner, MD, with the primary goal of testing
whether serial imaging, biomarker, and clinical and
neuropsychological assessments can be combined to
measure the progression from MCI to AD. For up-to-date
information, see www.adni-info.org. Inclusion and clinical
diagnosis criteria for ADNI have been described previ-
ously [28, 29]. We included subjects from ADNI who
received MRI, tau-PET (flortaucipir-PET, FTP-PET), and
Aβ-PET (florbetapir- or florbetaben-PET) and underwent
full neuropsychological testing, and had these data avail-
able in the ADNI data repository in August 2018, when
our study began. Only subjects that were Aβ positive, as
determined by Aβ-PET and a standard threshold [30, 31]
were included for statistical analysis to focus our study on
participants who were on the AD pathophysiological con-
tinuum [32]. The Aβ-PET scan that was acquired closest
in time to the tau-PET (time between Aβ-PET and tau-
PET: mean = 1.12 years, SD = 1.57 years) scan was used to
determine Aβ positivity.
MRI acquisition and processing
An overview of the image processing steps used in our
study is outlined in Fig. 1. Briefly, raw T1 MR images were
downloaded in DICOM format from the ADNI data portal.
Spatial distortions in MR images resulting from gradient
nonlinearities were corrected using scanner-specific param-
eters [33]. Corrections for nonuniformity in signal intensity
were then applied [34]. FreeSurfer (version 6.0) was used to
automatically segment and parcellate each structural MRI,
reconstruct the cortical surface, and measure thickness at
each vertex on the cortical mantle [35, 36].
We also defined each subject’s inferior cerebellar gray
matter, which was used as the reference region in PET
analyses (see the “PET acquisition and processing” sec-
tion). The MRI was segmented into tissue probability
maps with SPM12 (www.fil.ion.ucl.ac.uk/spm). Then, the
spatially unbiased atlas template of the cerebellum and
brainstem toolbox (SUIT, http://www.diedrichsenlab.
org/imaging/suit.htm) was used to reverse normalize the
SUIT template to the participants’ native space MRI.
PET acquisition and processing
FTP-PET was conducted to estimate the extent of tau
pathology. FTP-PET images were downloaded from the
ADNI portal in the most preprocessed form: realigned
to the first frame, averaged across frames, voxel sizes
standardized, and resolution made uniform across sites
[37]. These preprocessed images were coregistered to
the subject’s temporally closest MRI. These co-registered
FTP-PET images were then converted into standard up-
take value ratio (SUVr) images by normalizing the im-
ages to mean FTP uptake in the inferior cerebellar gray
matter [38]. The individual SUVr volumes were then
projected onto each individual’s cortical surface model
by sampling from points half-way between the white and
pial surfaces.
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Processing for surface-based analyses
Prior to conducting vertex-wise analyses (see the “Statistical
analysis” section), the individual thickness maps and FTP
maps were brought into a common space (fsaverage
space) using spherical-based registration methods [39].
Furthermore, because cortical thickness and FTP datasets
differed in spatial resolution in the surface maps, differen-
tial smoothing was applied to the thickness and FTP
surface maps to obtain similar spatial resolutions along
the cortical mantle prior to surface-based analysis. Kernels
of 15mm and 5mm were used for the thickness and FTP
maps, respectively.
Processing for region-of-interest analyses
In addition to surface-based vertex-wise analyses, we also
performed ROI analyses using partial volume corrected
(PVC) regional FTP data. The Geometric Transfer Matrix
[40] approach for PVC was applied, in combination with
FreeSurfer-parcellated ROIs from the Desikan-Killiany
atlas [41] and SPM12 tissue segmentations as described
previously [38]. For regional cortical thickness, we used
the average thickness of each Desikan-Killiany ROI as
outputted by FreeSurfer.
Neuropsychological assessment
Participants underwent neuropsychological testing to
assess performance across cognitive domains. We used
scores from their exam that was closest in time to their
FTP-PET date (time between neuropsychology visit and
FTP-PET: mean = 0.60 years, SD = 0.78 years). We used
various tests scores to represent the domains in ques-
tion: the Rey Auditory Verbal Learning Test (RAVLT)
and Logical Memory (LM) tests were used to assess
learning and memory. We analyzed the RAVLT sum of
all correctly learned words across trials 1 through 5
(RAVLT learning), RAVLT delayed recall, LM immediate
recall, and LM delayed recall. To assess verbal fluency
and naming abilities, we examined scores from the
category fluency: animals and the Multilingual Naming
Test (MINT). Lastly, to assess constructional abilities,
processing speed, and executive function, we analyzed
clock drawing score, clock copying score, and scores
from parts A and B of the Trail Making Test (TMT),
respectively. For all statistical analyses that involved
TMT Part A or TMT Part B, scores were multiplied by
− 1 so that lower scores indicated worse cognition.
Statistical analysis
Surface-based analysis
We performed surface-based general linear model ana-
lyses as implemented in FreeSurfer to explore the relation-
ships between tau and cognition, and between cortical
thickness and cognition. We used surfaced-based analysis
because surface-based registration offers a more accurate
alignment of cerebral cortex across subjects than volume-
based registration [42] and because 2D smoothing across
Fig. 1 Flow diagrams for subject inclusion and processing of neuroimaging data in our study. a The steps used for assembling the study sample.
b The steps used for image processing for surface-based vertex-wise analysis. Abbreviations: SUVr: standard uptake value ratio; FTP: flortaucipir;
mm: millimeters
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the surface helps prevent smoothing across different tissue
types in the PET data [43]. Vertex-wise analyses were
performed between FTP-PET and scores on each cog-
nitive test, and between cortical thickness and scores
on each cognitive test, with regressors for age, sex,
education, and time-delay between scan and cognitive
test administration. Model contrasts tested the hypo-
thesis that more tau or thinner cortex (in separate
models) was associated with worse cognitive per-
formance. A Monte Carlo simulation method [44] was
implemented for cluster exclusion and multiple com-
parisons correction, using a cluster-forming threshold
of -log(P value) > 4 or P value < 0.0001, and a cluster-
wise threshold P value < 0.05. All statistical surface
maps are displayed at a threshold of -log(P value) > 4
or P value < 0.0001 unless otherwise specified. We also
performed diagnosis-stratified surface-based analyses,
within CN, MCI, and AD subjects.
Domain-specificity analysis
Visual inspection of the FTP-cognition association maps
suggested that there may exist cognitive domain-specific
FTP retention patterns. To this end, we performed post
hoc pairwise Meng’s tests [45] between the FTP-cognition
partial correlations maps (vertex-wise P value < 0.005)
[46]. Meng’s test compares two dependent correlations
and allows us to determine whether FTP is more related
to one cognitive test versus another at each point on the
cortical surface. Meng’s test was performed pairwise for
the statistical maps from FTP vertex analyses with RAVLT
learning, RAVLT delayed recall, category fluency, and
TMT part A. These 4 tests were chosen because they had
qualitatively similar topographical associations with tau as
for LM immediate recall, LM delayed recall, MINT, and
clock drawing, respectively. To limit the number of verti-
ces examined, Meng’s test was only performed in vertices
that survived cluster correction in either of the analyses
being compared.
The domain-specificity analysis was also performed
for the partial correlation maps from the surface-
based thickness-cognition analyses. The same subset
of tests—RAVLT learning, RAVLT delayed recall,
category fluency, and TMT part A—were used for
the domain-specificity thickness analyses. These
results are reported in Additional file 1.
Region-of-interest analyses
To re-capitulate our vertex-wise analysis results at the
ROI level, we performed ROI correlational analyses. We
computed partial correlations between regional PVC-
FTP and cognitive test score, after each variable was
regressed onto age, sex, education, and time-delay be-
tween the date of scan and date of cognitive test admin-
istration. This correlational analysis was done for each
ROI and cognitive test pair. This analysis was repeated
for regional thickness, instead of regional PVC-FTP.
To explore the question of whether regional tau was
associated with cognition, independently of regional
thickness, we performed the following ROI analysis. We
again computed partial correlations between regional
PVC-FTP and cognitive test score. However, in this case,
we regressed each variable onto regional thickness, in
addition to age, sex, education, and time-delay between
scan and cognitive test. This allowed the examination of
associations between regional PVC-FTP and cognition,
independent of regional thickness. Results from our ROI
analyses are displayed in correlation matrices in Fig. 5.
In these analyses, we excluded FreeSurfer-defined re-
gions that correspond to Braak stage 6 [13] as they likely
exhibit little variability in FTP signal across the group.
We applied a threshold of P value < 9.9e−5 to each cor-
relation matrix, which corresponds to a family-wise error
(FWE) corrected P value of 0.05 for each matrix. Lastly,
in the PVC methods we used, medial and lateral orbito-
frontal were combined into a single ROI, pars orbitalis,
opercularis, and triangularis were combined into a single
ROI, and rostral and caudal middle frontal were com-
bined into a single ROI.
Results
Subject characteristics
A total of 134 ADNI participants met study criteria (Aβ
positive, received tau-PET imaging, received MRI, and
underwent the neuropsychology battery). Three subjects
were excluded as their structural MRI did not successfully
process through FreeSurfer or their MRI had substantial
motion artifact, leaving us with 131 participants to examine.
Of these participants, 55 had a diagnosis of cognitively nor-
mal, 46 with mild cognitive impairment, and 30 with AD.
The average participant age was 77.8 (±7.3) years and 65 of
the participants were female. Participant demographics and
a summary of cognitive test scores are shown in Table 1.
Associations between tau and cognitive function
Learning and Memory
In general, worse scores on the RAVLTand LM were asso-
ciated with more FTP binding (Fig. 2a). Visual inspection
of the statistical maps revealed that lower cognitive scores
were associated with FTP in medial, inferior, lateral tem-
poral cortex and also in medial and lateral parietal cortex.
Notably, there were stronger associations in frontal re-
gions for RAVLT learning and LM immediate recall than
for RAVLT delayed recall and LM delayed recall,
respectively.
Fluency and naming
Lower performance on category fluency and MINT was
also associated with greater FTP, as shown in Fig. 2b.
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Significant correlations were present in the left frontal
cortex and temporal, parietal, and lateral occipital cor-
tex and were mostly left lateralized (Additional file 1:
Figure S3).
Visuospatial, executive function, and processing speed
Compared to learning, memory, fluency, and naming
tests, the clock copying and TMT performance had
greater associations with FTP in posterior regions, includ-
ing more superior parietal cortex (Fig. 2c). In addition,
clock drawing, clock copying, and TMT part A also in-
volved the medial temporal cortex to a lesser extent
(Fig. 2c) than tests of learning, memory, and language.
Compared to TMT part A, the association between FTP
and TMT part B had more inferior and medial temporal
lobe involvement.
Fig. 2 Surface-based analysis demonstrates that FTP retention is associated with cognitive scores. a Performance on learning and memory tests
are associated with tau in temporal, parietal, and lateral frontal cortex. b Fluency and naming abilities are related to tau in temporal, parietal,
frontal, and lateral occipital cortex, with left-sided laterality. c Visuospatial function and processing speed are also related to tau in lateral frontal,
lateral temporal, and parietal cortex. Plots are in -log(P value) scale and vertex values range from -log (4) to -log (8). Cool colors indicate that
higher FTP retention is related to worse cognitive performance. For multiple-comparisons correction, a cluster-forming threshold of -log(P value)
> 4 or P value < 0.0001, and a cluster-wise threshold P value < 0.05 were used. Results from vertex-wise analyses with LM, Clock Copying, and
TMT part B displayed similar associations as RAVLT, Clock Drawing and TMT part A, respectively, and can be found in Additional file 1: Figure S1a.
Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; MINT, Multilingual Naming Test; TMT, Trail Making Test
Table 1 Subject demographics and cognitive test scores by diagnostic group
Variable CN MCI AD All subjects Domains tested
N (%female) 55 (56.3%) 46 (39.1%) 30 (53.3%) 131 (49.6%)
Age 77.3 (6.3) 77.5 (7.6) 79.0 (8.5) 77.8 (7.3)
RAVLT learning 45.7 (10.9) 31.9 (9.0) 25.6 (9.9) 36.3 (13.1) Learning
RAVLT delayed recall 7.7 (4.7) 2.8 (3.5) 1.5 (3.0) 4.6 (4.8) Memory
LM immediate recall 15.0 (3.2) 9.8 (4.9) 6.0 (5.25) 11.1 (5.7) Memory
LM delayed recall 14.0 (3.7) 7.5 (5.2) 2.8 (4.6) 9.1 (6.3) Memory
Category fluency—animals 22.0 (5.1) 16.5 (5.2) 12.5 (4.5) 17.9 (6.3) Language
MINT* 30.2 (2.4) 28.6 (3.9) 26.4 (5.1) 28.9 (3.8) Language
Clock drawing 4.8 (0.5) 4.2 (0.9) 3.8 (1.6) 4.4 (1.1) Visuospatial
Clock copying 4.7 (0.8) 4.7 (0.5) 4.3 (1.1) 4.6 (0.8) Visuospatial
Trail Making Test A† 31.9 (7.7) 41.3 (19.4) 60.3 (36.2) 41.7 (24.0) Executive function and processing speed
Trail Making Test B† 81.6 (40.2) 128.5 (82.2) 202.2 (99.3) 125.7 (86.6) Executive function and processing speed
Values are mean ± SD unless otherwise noted
Abbreviations: N number of participants, SD standard deviation, RAVLT Rey Auditory Verbal Learning Test, LM logical memory, MINT Multilingual Naming Test, CN
cognitively normal, MCI Mild Cognitive Impairment, AD Alzheimer’s disease
*Since MINT was added to the ADNI neuropsychology battery only recently, MINT scores were missing for 26 of our study participants
†In the Trail Making Test, a higher score denotes worse performance
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Associations between thickness and cognitive function
Learning and memory
Worse scores on the RAVLT and LM tests were associated
with thinner medial and lateral temporal cortices and with
medial parietal cortices (Fig. 3a).
Fluency and naming
The topographies of the relationships between thickness
and category fluency, and between thickness and MINT,
were similar to the topographies from the thickness-RAVLT
and thickness-LM associations (Fig. 3b). The thickness-
category fluency association involved more medial
parietal cortex than the thickness-MINT association.
Visuospatial, executive function, and processing speed
Poorer clock drawing and TMT scores were associated
with reduced thickness in medial and parietal cortex,
and inferior temporal cortex (Fig. 3c). Clock copying
was not significantly related to thickness anywhere in
the cortical mantle.
Visual assessment of the statistical maps from Figs. 1
and 2 revealed that the association between cortical
thickness and cognition, are less widespread than those
between FTP and cognition. Finally, in the diagnosis-
stratified surface-based analyses, we found no robust
associations between tau and cognition or between
thickness and cognition.
Domain-specificity analysis
Findings from Meng’s test domain specificity analyses
are shown in Fig. 4. Pairwise comparisons between tau-
cognitive function associations revealed that the asso-
ciation between FTP and TMT part A was stronger in
the superior parietal areas of the cortex than the other
FTP-cognition associations. The relationship between
FTP and RAVLT learning was stronger than that
between FTP and RAVLT delayed recall in the left
lateral temporoparietal cortex, left medial parietal cortex,
left posterior cingulate cortex, left inferior temporal
cortex, and the left dorsolateral frontal cortex. The FTP-
category fluency association was stronger in the left
anterior temporal lobe, bilateral medial orbitofrontal, and
bilateral insula than the FTP-TMT part A association.
The results from the domain-specificity analyses from
the thickness-cognition associations are displayed in
Additional file 1: Figure S2. In brief, Meng’s test analyses
did not elucidate any notable domain-specific correlation
patterns between thickness and cognitive function.
Region-of-interest analysis
As was the case for the vertex-wise analyses, the ROI
analyses showed that FTP was related to performance on
each cognitive test in broad areas of the cortex (Fig. 5b).
Furthermore, the ROI FTP-cognition associations showed
similar topographies as the vertex-wise FTP-cognition asso-
ciations. Temporal, parietal, and posterior portions of the
Fig. 3 Surface-based analysis demonstrates that cortical thickness is associated with cognitive scores. a Learning and memory abilities are related
to cortical thickness in temporal cortex and medial parietal cortex. b Performance on fluency and naming tests are associated with thickness in
temporal and medial parietal cortex. c Visuospatial function and processing speed are related to thickness in inferior and lateral temporal, and
medial and lateral parietal cortex. Plots are in -log(P value) scale and vertex values range from -log (4) to -log (8). Warm colors indicate that
thicker cortex is related to better cognitive performance. For multiple-comparisons correction, a cluster-forming threshold of -log(P value) > 4 or
P value < 0.0001, and a cluster-wise threshold P value < 0.05 were used. Results are shown for the same cognitive tests as Fig. 1. Results for the
rest of the cognitive tests can be found in Additional file 1: Figure S1b. Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; MINT, Multilingual
Naming Test; TMT, Trail Making Test
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cingulate were consistently involved across tests. However,
TMT, clock drawing, and clock copying tau showed a rela-
tively greater predilection for posterior parts of the cortex
compared to tests of learning, memory, fluency, and
naming tests. Regional cortical thickness was also related to
cognition, though the associations were much more sparse
than the ROI FTP-cognition relations (Fig. 5a). The
regional thickness associations were limited to temporal
cortex and left parietal cortex.
Lastly, even after accounting for regional thickness, ROI
FTP remained significantly associated with cognition
(Fig. 5c), though the magnitudes of the partial correlations
were reduced.
Discussion
We used flortaucipir-PET and structural MRI to assess
the relationships of tau and cortical thickness with per-
formance in several domains of cognition. We found
that worse cognition is related to greater tau burden and
thinner cortex. We also found that the tau-cognition
relationships were present in a domain-specific manner
and were more widespread than the thickness-cognition
relationships. We discuss our findings in the context of
previous studies that have examined in vivo tau, atrophy,
and cognition.
The implication of medial temporal, medial parietal, and
lateral parietal tau load with memory and with global cog-
nition has been well documented and replicated by several
groups since the development of in vivo tau methods [13,
47]. Our findings are congruent with those previous
studies and build upon them in a number of ways. For
example, in our surface-based tau analyses, we found rela-
tively greater left prefrontal cortex involvement in the
RAVLT learning than the RAVLT delayed recall and also
greater left prefrontal involvement in the LM immediate
recall than LM delayed recall. This first highlights that the
association between tau and AD-related learning and
memory impairment is not restricted to temporal and par-
ietal cortex. Furthermore, the implication of left prefrontal
cortex is consistent with data from functional imaging and
lesion studies that have localized verbal learning and
verbal working memory to left frontal cortex [48, 49],
suggesting that the specific location of tau deposition
relates to specific aspects of cognitive loss.
The regional specificity between tau and cognitive
impairment has been demonstrated in the context of
early-onset, non-amnestic forms of AD, where clinical
variants exhibit different topographies of tau that are con-
sistent with the clinical phenotype [24, 25]. There is now
also mounting evidence that, even in late-onset, amnestic
AD, tau burden regionally associates with performance on
Fig. 4 Meng’s test analyses show that FTP exhibits domain-specific relations with cognition. Yellow indicates that the cognitive measure noted
in the column had a stronger association with FTP at that vertex than the cognitive measure noted in row (P value < .005). Red indicates that the
cognitive measures noted in the row had a stronger association with FTP at that vertex than the cognitive measures noted in the column
(P value < 0.005). Meng’s test was limited to regions of the cortex that were significant after cluster-wise correction in the FTP-cognition or
thickness-cognition analysis. Abbreviations: RAVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test
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domain-specific tests of cognitive function above and
beyond learning and memory [27] and that this asso-
ciation maps onto the cortical circuitry underlying the
respective cognitive domain. This notion is supported by
the significant associations between tau and tests of
language, processing speed, visuospatial and executive
functions, and semantic knowledge that we found in our
study. Although there was spatial overlap between cogni-
tive tests in their associations with tau, particularly in early
Braak regions, there was also considerable heterogeneity.
This includes left-hemispheric laterality for tests of
language and stronger superior parietal involvement in
tests of processing speed and constructional ability com-
pared to tests of memory and language. These patterns of
tau-cognition associations mapped closely with the cor-
tical systems that are believed (based on functional
imaging and lesion studies) to support the specific cogni-
tive functions tested. The finding that TMT parts A and B
displayed stronger associations in parietal cortex com-
pared to tests of memory and language, for example, is
congruent with fMRI studies that have shown that tasks
involving numbers rely on parietal cortex [50] and that
the set-shifting necessary for successful completion of
TMT part B is supported by activation of intraparietal sul-
cus [51]. Taken together, our findings from surface-based
analyses with tau-PET are aligned with recent studies of
patients with early-onset [24, 25] [52] and late-onset AD
[27] that have demonstrated that performance in various
cognitive domains associates with tau along distinct topo-
graphic patterns.
Cortical thickness also correlated with performance
across tests, and these associations were topographically
similar to the tau-cognition associations. Both correlations
involved temporal and parietal cortex across cognitive
domains, whereas tests of processing speed and construc-
tional abilities showed stronger correlations with tau in
more posterior cortex than tests of memory and language.
However, the thickness-cognition relationships were more
spatially restricted than the tau-cognition relationships.
Although the order in which disease-related tau and
atrophy appear during aging and AD has been under
discussion [53], models of AD pathophysiology have
historically postulated primacy of tau pathology [54]. Our
finding that the tau-cognition associations were more
Fig. 5 Region-of-interest analyses showing the relationship between regional tau and cognition, and between regional thickness and cognition.
The value in each cell of the matrix shows the partial correlation between a regional thickness and cognition, b regional PVC-FTP and cognition,
and b between regional PVC-FTP and cognition, after accounting for regional thickness. The association of cognition with regional PVC-FTP or
regional thickness recapitulate our vertex-wise findings. Matrices are displayed at a threshold of P value < 9.9e−5. In b, the columns for medial
orbitofrontal and lateral orbitofrontal are identical, the columns for pars orbitalis, opercularis, and triangularis are identical, and the columns for
rostral and caudal middle frontal are identical. This is a consequence of the PVC methods we used (see the “Methods” section) which combine
individual FreeSurfer ROIs into larger ROIs. Abbreviations: PVC, Partial Volume Corrected; ROI, region-of-interest; AVDEL30MIN, RAVLT Delay;
AVSUM15, RAVLT Learning; CATANIMSC, Category Fluency—Animals; CLOCKSCOR, Clock Drawing; COPYSCOR, Clock Copying; LDELTOTAL, LM
Delay; LIMMTOTAL, LM Immediate; TRAASCOR, TMT Part A; TRABSCOR, TMT Part B
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widespread than the atrophy cognition associations is
consistent with this model, but future studies that assess
parallel longitudinal atrophy and tau will help to clarify
the temporal staging of these AD biomarkers.
Our results from the surface-based, vertex-wise analyses
shown in Figs. 2 and 3 demonstrate that there are areas of
the cortex where cognition is related to tau, but not to
cortical thickness. This is recapitulated in our ROI analyses.
We further showed in the ROI analyses that, even after
taking regional thickness into account, PVC-FTP still
predicted cognition. We interpret these findings to mean
that tau may exert an influence on cognition via mecha-
nisms that are independent of structural atrophy. There are
several potential pathways through which tau may induce
cognitive loss such as synaptic dysfunction and synaptic
loss. Some of these alterations, which can now be estimated
in vivo using PET [55], should be the focus of future studies
to provide a better view of how the hallmark AD patho-
logies like tau drive decline and to realize new potential
avenues for therapeutic intervention. We should note that
the widespread topography of tau-cognition associations
relative to thickness-cognition associations may be a conse-
quence of deriving the tau and cortical thickness measures
from different modalities. However, we applied a differential
smoothing procedure to account for this and, moreover, a
recent study by Bejanin and colleagues [25] also reported
data suggestive of an atrophy-independent effect of tau on
cognition, lending further credence to our interpretation.
Our findings have several practical implications. For
example, a critical aim for designing a well-powered
clinical trial is enrolling individuals that are on the verge
of AD-related cognitive decline. Although our data are
cross-sectional, the robust relation between tau and cog-
nition may indicate that tau burden is a better and more
sensitive predictor of imminent decline than is cortical
thickness. There are several potential reasons as to why
tau-PET may be a more sensitive tool for detecting
decline. As we discussed above, tau may precede neu-
rodegeneration [56] and begin to exert its affect on
cognition prior to discernable atrophy. Furthermore,
cross-sectional MRI-based estimates of atrophy may be
affected by premorbid, inter-individual variability in
thickness. Related to this, there is some evidence that
atrophy measures derived from longitudinal MRI may
offer predictive power beyond cross-sectional measures
of atrophy in forecasting cognitive decline [57]. Thus, it
will be important to incorporate longitudinal MRI if
seeking to determine which imaging measures are most
useful in clinical trial contexts. Lastly, because we
focused on cortical patterns of tau and atrophy as they
relate to cognition, we excluded hippocampal atrophy
from our analyses. Hippocampal atrophy has been
shown to be an indicator of imminent cognitive decline
[58, 59] so estimates of hippocampal volume loss, in
addition to cortical thinning, should be included in stud-
ies seeking to address the relative utilities of MRI and
PET in predicting decline for powering clinical trials.
With further regard to clinical trials, there are now
several compounds in the AD pipeline whose mechanism
of action involves targeting tau pathology [60]. For these
trials, it will be critical to identify individuals that are cur-
rently undergoing, or are expected to undergo, cognitive
changes that are related to tau, rather than changes due to
non-AD neurodegenerative, neuropsychiatric, or normal
aging processes. Our data first demonstrate that noninva-
sive and economical neuropsychological tests like those
used in ADNI can detect tau-related changes, supporting
their potential utility as a screening tool. In addition, given
that tau correlated with cognition in several domains, our
data highlight the importance of designing neuropsycho-
logical batteries or composites for clinical trials that eva-
luate functions beyond memory.
Some limitations to our study should be acknowledged.
FTP has been shown to exhibit off-target binding to
choroid plexus in the areas adjacent to the hippocampus
[61], to monoamine oxidases [62], and others. Newer
generations of radiotracers that bind more specifically to
tau [63] will minimize this problem in future studies.
Another limitation is that our sample of participants is
relatively skewed to early disease stages. This may have
produced a limited range in cognitive measures and FTP
signal, and hence, could have limited our ability to detect
some tau-cognition and thickness-cognition relationships
that may be present in AD. We were further limited by
the brief battery in ADNI. Future studies with more
extensive testing, for example, testing memory with non-
verbal as well as verbal stimuli, will allow for broader
understanding of tau-cognition relationships. The final
shortcoming of our study is the small sample size, which
potentially explains the failure to find meaningful tau-cog-
nition and thickness-cognition associations in the diagno-
sis-stratified analyses. Future studies in larger cohorts may
demonstrate relationships within diagnostic groups, help-
ing to explain the staging of tau-atrophy relationships
across the spectrum of the disease.
Conclusions
In a group of individuals along the AD spectrum, we found
that cognitive decline in specific domains parallels the
deposition of tau into the cortical systems that are thought
to be responsible for subserving those domains. Our vertex
and ROI analyses also revealed that there are areas of
cortex where cognition is related to tau, but not cortical
thickness, suggesting that tau may have an effect on cogni-
tion via mechanisms that are, at least in part, independent
of significant atrophy. These data are consistent with pre-
vious studies and offer further insights into the pathophy-
siology underlying cognitive impairment in AD.
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